Evidence map›Paper›PMID 36286048›Full record

ReviewCurrent issues in molecular biology2022

Therapeutic Use and Chronic Abuse of CNS Stimulants and Anabolic Drugs.

Daniela Coliță, Cezar-Ivan Coliță, Dirk M Hermann, Eugen Coliță, Thorsten R Doeppner, Ion Udristoiu, Aurel Popa-Wagner

Open access · goldAbstract readReview
In one paragraph

Review in Current issues in molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Biomarkers of cognitive and memory decline in psychotropic drug users.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Daniela ColițăDoctoral School, University of Medicine and Pharmacy "Carol Davila", 020276 Bucharest, Romania.
Cezar-Ivan ColițăDoctoral School, University of Medicine and Pharmacy "Carol Davila", 020276 Bucharest, Romania.ORCID 0000-0001-5700-8511
Dirk M HermannChair of Vascular Neurology, Dementia and Ageing, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Eugen ColițăDoctoral School, University of Medicine and Pharmacy "Carol Davila", 020276 Bucharest, Romania.
Thorsten R DoeppnerDepartment of Neurology, University Medical Center Göttingen, 37075 Gottingen, Germany.
Ion UdristoiuDepartment of Psychiatry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Aurel Popa-WagnerChair of Vascular Neurology, Dementia and Ageing, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0003-4574-8605
Carol Davila University of Medicine and Pharmacy · ROUniversity of Medicine and Pharmacy of Craiova · ROUniversitätsklinikum Gießen und Marburg · DEUniversity of Duisburg-Essen · DE

Funding

Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii 136/2020Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii 192/2020Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PN-III-P4-ID-PCE-2020-059
6 · The paper itself

Abstract

The available evidence suggests that affective disorders, such as depression and anxiety, increase risk for accelerated cognitive decline and late-life dementia in aging individuals. Behavioral neuropsychology studies also showed that cognitive decline is a central feature of aging impacting the quality of life. Motor deficits are common after traumatic brain injuries and stroke, affect subjective well-being, and are linked with reduced quality of life. Currently, restorative therapies that target the brain directly to restore cognitive and motor tasks in aging and disease are available. However, the very same drugs used for therapeutic purposes are employed by athletes as stimulants either to increase performance for fame and financial rewards or as recreational drugs. Unfortunately, most of these drugs have severe side effects and pose a serious threat to the health of athletes. The use of performance-enhancing drugs by children and teenagers has increased tremendously due to the decrease in the age of players in competitive sports and the availability of various stimulants in many forms and shapes. Thus, doping may cause serious health-threatening conditions including, infertility, subdural hematomas, liver and kidney dysfunction, peripheral edema, cardiac hypertrophy, myocardial ischemia, thrombosis, and cardiovascular disease. In this review, we focus on the impact of doping on psychopathological disorders, cognition, and depression. Occasionally, we also refer to chronic use of therapeutic drugs to increase physical performance and highlight the underlying mechanisms. We conclude that raising awareness on the health risks of doping in sport for all shall promote an increased awareness for healthy lifestyles across all generations.

Indexed as

agingcognitive declinedementiadepressiondopingrecreational drugsrestorative therapiesstroketraumatic brain injuries

Identifiers

PMID36286048
PMCPMC9600088
OpenAlexW4306366813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.